No connection

Search Results

ABUS vs TALK

ABUS
Arbutus Biopharma Corporation
BEARISH
Price
$4.53
Market Cap
$872.0M
Sector
Healthcare
AI Confidence
85%
TALK
Talkspace, Inc.
NEUTRAL
Price
$5.18
Market Cap
$865.5M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ABUS
--
TALK
129.5
Forward P/E
ABUS
-27.41
TALK
23.55
P/B Ratio
ABUS
11.38
TALK
7.38
P/S Ratio
ABUS
61.92
TALK
3.78
EV/EBITDA
ABUS
-29.91
TALK
128.23

Profitability

Gross Margin
ABUS
-79.23%
TALK
39.82%
Operating Margin
ABUS
-727.31%
TALK
6.08%
Profit Margin
ABUS
-237.88%
TALK
3.4%
ROE
ABUS
-38.52%
TALK
6.65%
ROA
ABUS
-14.94%
TALK
1.44%

Growth

Revenue Growth
ABUS
-33.2%
TALK
29.3%
Earnings Growth
ABUS
--
TALK
181.1%

Financial Health

Debt/Equity
ABUS
0.05
TALK
--
Current Ratio
ABUS
15.73
TALK
6.38
Quick Ratio
ABUS
15.52
TALK
6.25

Dividends

Dividend Yield
ABUS
--
TALK
--
Payout Ratio
ABUS
0.0%
TALK
0.0%

AI Verdict

ABUS BEARISH

ABUS exhibits severe financial distress signals with a Piotroski F-Score of 0/9, indicating extreme weakness in operational and financial health. The company reports massive negative margins, declining revenue, and unprofitable operations, with no meaningful cash flow or profitability. While the low debt-to-equity ratio and high current ratios suggest strong liquidity, they are likely inflated by non-operational cash reserves. The absence of a Graham Number and intrinsic value estimate reflects a lack of sustainable earnings, and the stock trades at a premium valuation despite deteriorating fundamentals. Analysts offer no consensus, and insider activity is neutral, reinforcing a lack of confidence.

Strengths
High current and quick ratios (15.73 and 15.52) indicate strong short-term liquidity
Low debt-to-equity ratio (0.05) suggests minimal leverage risk
Recent 1-year return of +34.4% shows strong price momentum despite fundamentals
Risks
Piotroski F-Score of 0/9 signals severe financial distress and operational failure
Negative profit margins (up to -237.88%) and declining revenue (-33.20% YoY) indicate deteriorating business model
No operating cash flow or free cash flow data available, raising concerns about sustainability
TALK NEUTRAL

TALK presents a classic growth-vs-value conflict. While the Piotroski F-Score of 4/9 indicates stable financial health and the company has successfully transitioned to profitability with explosive earnings growth (181% YoY), the valuation is disconnected from deterministic baselines. The stock trades at $5.18, significantly exceeding both the Graham Number ($0.79) and Intrinsic Value ($1.18), suggesting a massive growth premium. Strong liquidity (Current Ratio 6.38) offsets the lack of an Altman Z-Score, but bearish insider activity and a weak technical trend temper the bullish growth narrative.

Strengths
Strong revenue growth of 29.30% YoY
Successful transition to profitability with 181.10% earnings growth
Exceptional liquidity with a Current Ratio of 6.38
Risks
Extreme valuation premium (P/E of 129.50)
Significant divergence from Graham Number ($0.79) and Intrinsic Value ($1.18)
Bearish insider sentiment with CTO selling shares

Compare Another Pair

ABUS vs TALK: Head-to-Head Comparison

This page compares Arbutus Biopharma Corporation (ABUS) and Talkspace, Inc. (TALK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile